Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts
This Resource is Outdated
Please visit our Q1 2026 Bullseye Charts for the latest version.
Q3 2025 Psychedelic Drug Development Bullseye Chart
By Indication Grouping
In addition to our entire pipeline Bullseye Chart, above, we have also produced a Bullseye that focuses on Phase 2+ assets, grouped by broad indication.
Basic
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Benefits
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||